Structural basis of respiratory syncytial virus neutralization by motavizumab
- NIH
Motavizumab is {approx}tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
- Research Organization:
- Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 1002273
- Journal Information:
- Nat. Struct. Mol. Biol., Journal Name: Nat. Struct. Mol. Biol. Journal Issue: (2) ; 02, 2010 Vol. 17; ISSN 1545-9985; ISSN 1545-9993
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes
Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Journal Article
·
Fri Sep 16 00:00:00 EDT 2011
· J. Virol.
·
OSTI ID:1020595
Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
Journal Article
·
Thu Jun 28 00:00:00 EDT 2012
· J. Mol. Biol.
·
OSTI ID:1040898
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Journal Article
·
Mon Oct 17 00:00:00 EDT 2016
· Proceedings of the National Academy of Sciences of the United States of America
·
OSTI ID:1333419